secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-04-01T23:59:59+00:00
Accession:  0001558370-22-004990
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage FY2021 net loss widens to $8.0M on $3.3M litigation charge and higher legal costs
--------------------------------------------------------------------------------

- Q4 2021 net loss of $5.9M ($0.55/share) vs $1.0M loss in Q4 2020; FY2021 loss $8.0M ($0.79/share).
- Loss increase driven by $3.3M contingency charge for wrongful death litigation and $1.3M legal fees for insurance coverage.
- Operating cash at Dec 31, 2021: $1.2M; management expects funding into early Q3 2022.
- Proceeds of $2.8M from private placements (1,372,464 shares + warrants) helped offset $2.6M operating cash burn.
- R&D costs decreased $0.5M in FY2021; notes payable forgiveness contributed $0.4M gain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022004990/0001558370-22-004990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022004990/tmb-20220401x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-004990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer